Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study on antibody levels after COVID-19 vaccination
ChiCTR2100051264Phase 4Recruiting
- Sponsor
- Luzhou Center for Disease Control and Prevention
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Covidful in coronavirus disease 2019 (COVID-19), sponsored by Luzhou Center for Disease Control and Prevention. Primary endpoint: SARS-CoV-2 neutralizing antibody. Started Sep 2021; status: recruiting.
02
Drugs
Covidful
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100051264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051264.